A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a significant weight reduction compared with placebo, according to top-line results from a phase 1b/2a trial. Amycretin (Novo Nordisk) is a once-weekly subcutaneous agent currently under development for the treatment of overweight or obesity and type 2 diabetes. There were
Among patients with obstructive sleep apnea, those treated with sleep surgery vs. CPAP had decreased odds for motor vehicle accident incidence, according to results published…
The vast majority of people in a study with long COVID had experienced multiple SARS-CoV-2 infections over the course of a 4-year period, researchers reported.
KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2025, Cynthia A. Matossian, MD, discusses the launch of Healio Community and the wide…
Follicular thyroid cancer with bone involvement was associated with a significantly elevated risk for brain metastases among women.
The CDC’s primary medical journal for disseminating public health information went unpublished this week — seemingly for the first time ever — amid a communications…
KOLOA, Hawaii — Ophthalmologists must know how to identify and manage pseudoexfoliation glaucoma, one of the most damaging forms of the disease, according to a…
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Olfactive Biosolutions Granted Third Dual GLP-1 / GIP Patent to Repurpose…
Rheumatologists report largely adhering to American College of Rheumatology guidelines for gout management, but show notable divergence with the recommended dosages of urate-lowering therapies, according…
